<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oxytocin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oxytocin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oxytocin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10918" href="/d/html/10918.html" rel="external">see "Oxytocin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709190"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, oxytocin is not indicated for elective induction of labor.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F205493"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pitocin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F205529"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Oxytocic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F205497"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>The use of one standardized concentration and administration protocol (eg, the rate and interval for dose increases) for the induction or augmentation of labor and the management of postpartum uterine bleeding is recommended to prevent errors</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32778395','lexi-content-ref-Smetzer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32778395','lexi-content-ref-Smetzer.1'])">Ref</a></span>). Dosage is individualized for each patient using the lowest effective dose, determined by uterine response (ie, contractions and fetal heart rate).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2be7b745-9014-4aa0-aea7-41a4b0b90529">Induction or stimulation of labor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Induction or stimulation of labor:</b> Administration requires the use of an infusion pump. <b>Note: </b>The ideal dosing regimen has not been determined and various protocols are available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19623003','lexi-content-ref-33345911','lexi-content-ref-36725134','lexi-content-ref-20451894']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19623003','lexi-content-ref-33345911','lexi-content-ref-36725134','lexi-content-ref-20451894'])">Ref</a></span>); refer to institution-specific protocol. To prevent medication errors, the dose should be administered using a ready-to-use standardized infusion protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29240650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29240650'])">Ref</a></span>). Consider discontinuing the oxytocin infusion once cervical dilation is 5 to 6 cm and adequate contractions are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33345875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33345875'])">Ref</a></span>). Discontinue the oxytocin infusion immediately in the event of uterine hyperactivity and/or fetal distress. If uterine contractions become too powerful, the infusion can be stopped abruptly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial:</i> IV:</b> 0.5 to 1 milliunits/minute; gradually increase dose in increments of 1 to 2 milliunits/minute every 30 to 60 minutes until desired contraction pattern is established; dose may be decreased by similar increments after desired frequency of contractions is reached and labor has progressed to 5 to 6 cm cervical dilation. Higher infusion rates may be needed prior to term due to a lower sensitivity of the uterus. Infusion rates up to 6 milliunits/minute provide oxytocin levels similar to those with spontaneous labor; rates &gt;9 to 10 milliunits/minute are rarely required in patients at term.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Low-dose regimens (off-label dose):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: <b>IV:</b> 0.5 to 2 milliunits/minute; incrementally increase by 1 to 2 milliunits/minute every 15 to 40 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19623003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19623003'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>OR</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: <b>IV:</b> 2 milliunits/minute; incrementally increase by 2 milliunits/minute every 30 minutes to a maximum of 20 milliunits/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33345911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33345911'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>High-dose regimens (off-label dose):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: <b>IV:</b> 6 milliunits/minute; incrementally increase by 3 to 6 milliunits/minute every 15 to 40 minutes. Reduce the incremental increase to 3 milliunits/minute if uterine tachysystole occurs; reduce the incremental increase to 1 milliunit/minute for recurrent uterine tachysystole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19623003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19623003'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>OR</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: <b>IV:</b> 4 milliunits/minute; incrementally increase by 4 milliunits/minute every 15 minutes to a maximum of 40 milliunits/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33345911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33345911'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Maximum dose:</b></i> Not well established; refer to institution-specific protocol. Dosage is individualized for each patient using the lowest effective dose, determined by uterine response (ie, contractions and fetal heart rate). Although some protocols suggest maximum doses, higher doses (eg, 90 milliunits/minute) have been used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10472877','lexi-content-ref-36725134','lexi-content-ref-36649339','lexi-content-ref-20451894']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10472877','lexi-content-ref-36725134','lexi-content-ref-36649339','lexi-content-ref-20451894'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Dose adjustment for oxytocin-induced uterine tachysystole:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Normal fetal heart rate (FHR): If management with maternal repositioning and administration of IV fluids (if needed) is not effective after 10 to 15 minutes, decrease oxytocin infusion by at least 50%. Discontinue oxytocin if uterine activity does not return to normal after an additional 10 to 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32778395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32778395'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Indeterminate or abnormal FHR: Discontinue oxytocin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32778395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32778395'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Restarting oxytocin infusion: Oxytocin may be resumed following resolution of uterine tachysystole when contraction frequency, intensity, and duration, and FHR are normal. If infusion was discontinued for less than 20 to 30 minutes, initiate oxytocin at no more than 50% of the rate that caused the tachysystole and gradually adjust dose based on protocol and maternal/fetal status. If infusion was discontinued for more than 30 to 40 minutes, resume infusion at original dose ordered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32778395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32778395'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If uterine contractions become too powerful, the infusion can be stopped abruptly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Duration of therapy:</i></b>Consideration may be given to discontinue the oxytocin infusion once cervical dilation is 5 to 6 cm and adequate contractions are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33345875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33345875'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f17d28fb-9b03-4f2c-89a1-065e70e821ec">Postpartum uterine bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postpartum uterine bleeding: Note:</b> Oxytocin is used for both prevention and treatment of postpartum hemorrhage associated with uterine atony following both vaginal and cesarean delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28526143','lexi-content-ref-33252891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28526143','lexi-content-ref-33252891'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Larger doses may be needed with unplanned cesarean deliveries if oxytocin was previously administered during labor; repeated doses may become ineffective due to desensitization of oxytocin receptors and changes in receptor density in the myometrium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21415725','lexi-content-ref-28526143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21415725','lexi-content-ref-28526143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oxytocin may be administered by slow IV bolus, IV infusion, or IM injection. Rapid IV bolus administration is associated with cardiovascular collapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28937571','lexi-content-ref-28526143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28937571','lexi-content-ref-28526143'])">Ref</a></span>); rapid IV boluses are not recommended for patients with cardiovascular risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30865585','lexi-content-ref-26773243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30865585','lexi-content-ref-26773243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">To prevent postpartum hemorrhage, IV is preferred over IM injection following vaginal delivery in patients who already have IV access (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32600245','lexi-content-ref-33252891','lexi-content-ref-32124015','lexi-content-ref-32439242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32600245','lexi-content-ref-33252891','lexi-content-ref-32124015','lexi-content-ref-32439242'])">Ref</a></span>). Either route of administration may be used in patients undergoing cesarean delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33252891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33252891'])">Ref</a></span>). Administer oxytocin during the third stage of labor after delivery of the placenta, delivery of the anterior shoulder, or after delayed umbilical cord clamping (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28937571','lexi-content-ref-30865585']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28937571','lexi-content-ref-30865585'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">The optimal IV regimen has not been established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34148721','lexi-content-ref-21415725','lexi-content-ref-28526143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34148721','lexi-content-ref-21415725','lexi-content-ref-28526143'])">Ref</a></span>); refer to institution-specific protocol. To prevent medication errors, the dose should be administered using a ready-to-use standardized infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29240650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29240650'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 10 units after delivery of the placenta.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30865585','lexi-content-ref-26773243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30865585','lexi-content-ref-26773243'])">Ref</a></span>) or 10 units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30865585','lexi-content-ref-26773243','lexi-content-ref-33252891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30865585','lexi-content-ref-26773243','lexi-content-ref-33252891'])">Ref</a></span>) may be given initially and can be followed by a maintenance infusion of up to 10 units/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30865585','lexi-content-ref-26773243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30865585','lexi-content-ref-26773243'])">Ref</a></span>). Maximum cumulative dose: 40 units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26773243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26773243'])">Ref</a></span>). Adjust infusion rate to sustain uterine contraction and control uterine atony.</p>
<p style="text-indent:-2em;margin-left:6em;">Lower bolus doses (0.5 to 3 units) for the prevention of postpartum bleeding have also been evaluated in patients undergoing elective cesarean delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20150347','lexi-content-ref-15516392','lexi-content-ref-30865585']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20150347','lexi-content-ref-15516392','lexi-content-ref-30865585'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="977b9e3f-7477-40b4-9597-dbb932a420bb">Adjunctive treatment of abortion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adjunctive treatment of abortion:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Incomplete, inevitable, or elective abortion: <b>IV: </b>10 units as an IV infusion after suction or a sharp curettage (used to help contract the uterus).</p>
<p style="text-indent:-2em;margin-left:4em;">Midtrimester elective abortion: <b>IV: </b>10 to 20 <b>milli</b>units/minute; maximum total dose: 30 units/12 hours (may decrease injection to abortion time).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990424"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987596"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F205464"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, hypertensive crisis, hypotension (Dyer 2011), subarachnoid hemorrhage, tachycardia (Dyer 2011), ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Water intoxication (severe water intoxication with seizure and coma is associated with a slow oxytocin infusion over 24 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Postpartum hemorrhage, uterine rupture</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Pelvic hematoma</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F205477"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to oxytocin or any component of the formulation; significant cephalopelvic disproportion; unfavorable fetal positions or presentations (such as transverse lies); fetal distress when delivery is not imminent; hypertonic or hyperactive uterus; contraindicated vaginal delivery (invasive cervical cancer, active genital herpes, prolapse of the cord, cord presentation, total placenta previa, or vasa previa); obstetrical emergencies where surgical intervention is favored; where adequate uterine activity fails to achieve satisfactory progress.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in the US labeling): Severe toxemia; prematurity or unripe cervix; predisposition to uterine rupture (eg, grand multiparity, overdistention of the uterus, previous caesarian delivery, other surgery involving the uterus); prolonged use in uterine inertia; factors predisposing to thromboplastin or amniotic fluid embolism (eg, prolonged retention of dead fetus, placental abruption); serious medical or obstetric conditions and any condition in which fetal distress already occurs; inability of physician to be in attendance</p></div>
<div class="block war drugH1Div" id="F205461"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antidiuretic effect: Oxytocin may produce intrinsic antidiuretic effect (ie, water intoxication). Severe water intoxication with convulsions, coma, and death may occur, particularly with large doses (40 to 50 milliunits/minute) administered as a slow infusion over 24 hours and if the patient is receiving additional fluids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Arrhythmias, hypotension, myocardial ischemia, peripheral vasodilation, and tachycardia have been reported following administration. The risk of adverse events is influenced by dose and route of administration and is increased in patients with cardiovascular disease. Use with extreme caution in hemodynamically unstable patients (Dyer 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">• Maternal deaths: Maternal deaths caused by hypertensive episodes, subarachnoid hemorrhage, or rupture of the uterus and fetal deaths have occurred with oxytocic medications when used for induction of labor or for augmentation in the first and second stages of labor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Uterine effects: High doses or hypersensitivity to oxytocin may cause uterine hypertonicity, spasm, tetanic contraction, or rupture of the uterus. Prolonged infusion of oxytocin may saturate uterine receptors, causing inadequate uterine contractions and prolonged labor (AWHONN [Simpson 2020], Vallera 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Labor induction: Oxytocin is used to initiate or improve uterine contractions in order to replicate spontaneous labor and achieve a vaginal delivery. Use for induction of labor is generally not recommended in the following conditions: Fetal distress, hydramnios, partial placenta previa, prematurity, borderline cephalopelvic disproportion, or conditions where there is a predisposition for uterine rupture (eg, previous major surgery on cervix or uterus, cesarean section, overdistention of the uterus, grand multiparity, past history of uterine sepsis or traumatic delivery).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Abortion: For the adjunctive management of abortion in the first trimester, curettage is generally considered primary therapy. Oxytocin infusion in second trimester abortion will often be effective; however, other therapy may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: IV preparations should be administered by adequately trained individuals familiar with its use and able to identify complications; continuous observation is necessary for all patients.<b> The use of one standardized concentration for the induction or augmentation of labor and the management of postpartum uterine bleeding is recommended to prevent errors</b> (AWHONN 2021; AWHONN [Simpson 2020]; ISMP [Smetzer 2022]). Administration of ready-to-use bags boldly labeled on both sides (to differentiate from other solutions), not bringing the prepared oxytocin infusion to the patient's bedside until needed, and the use of standardized order sets are additional best practice safety interventions (ISMP [Smetzer 2022]).</p></div>
<div class="block foc drugH1Div" id="F205472"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pitocin: 10 units/mL (1 mL, 10 mL, 50 mL) [contains chlorobutanol (chlorobutol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 units/mL (1 mL, 10 mL, 30 mL)</p></div>
<div class="block geq drugH1Div" id="F205457"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323589"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Oxytocin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 units/mL (per mL): $1.80 - $4.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Pitocin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 units/mL (per mL): $4.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867807"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 units/mL (1 mL, 5 mL, 10 mL)</p></div>
<div class="block adm drugH1Div" id="F205474"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>The use of one standardized concentration and administration protocol (eg, the rate and interval for dose increases) for the induction or augmentation of labor and the management of postpartum uterine bleeding is recommended to prevent errors</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32778395','lexi-content-ref-Smetzer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32778395','lexi-content-ref-Smetzer.1'])">Ref</a></span>). Administration of ready-to-use bags boldly labeled on both sides (to differentiate from other solutions), not bringing the prepared oxytocin infusion to the patient's bedside until needed, and the use of standardized order sets are additional best practice safety interventions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Smetzer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Smetzer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Induction or augmentation of labor:</b> IV administration requires the use of an infusion pump that allows minute-to-minute adjustments. The oxytocin solution can be piggybacked to an isotonic electrolyte infusion line proximal to the venipuncture site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19623003','lexi-content-ref-32778395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19623003','lexi-content-ref-32778395'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Incomplete or inevitable abortion:</b> Administer by IV infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postpartum uterine bleeding:</b> Administer by IV or IM. IM administration may be used when IV access is not available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34148721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34148721'])">Ref</a></span>). IV push is not recommended; rapid IV bolus administration is associated with cardiovascular collapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28937571','lexi-content-ref-28526143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28937571','lexi-content-ref-28526143'])">Ref</a></span>). Slow IV injections (5 or 10 units over 1 minute) are preferred for patients without cardiovascular risk factors; very slow injections (&gt;5 minutes) are preferred for patients with cardiovascular risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30865585','lexi-content-ref-26773243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30865585','lexi-content-ref-26773243'])">Ref</a></span>). Administration IV is preferred over IM injection for the prevention of postpartum hemorrhage following vaginal delivery in patients who already have IV access (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32600245','lexi-content-ref-33252891','lexi-content-ref-32124015','lexi-content-ref-32439242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32600245','lexi-content-ref-33252891','lexi-content-ref-32124015','lexi-content-ref-32439242'])">Ref</a></span>). Either route of administration may be used in patients undergoing cesarean delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33252891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33252891'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132765"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F205473"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Antepartum:</b> Initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. Induction of labor in patients with a medical indication (eg, Rh problems [isoimmunization], maternal diabetes, preeclampsia, at or near term) when delivery is in the best interests of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; stimulation or reinforcement of labor (as in selected cases of uterine inertia); adjunctive therapy in the management of incomplete or inevitable abortion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Oxytocin may also be used for other medical conditions in antepartum labor induction, including chronic or gestational hypertension, fetal compromise (eg, severe fetal growth restriction or oligohydramnios), or augmentation of labor, used when contractions are inadequate to produce a cervical change in dilation and effacement (ACOG 2009; AWHONN [Simpson 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postpartum:</b> To produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage.</p></div>
<div class="block off-label drugH1Div" id="F56509904"><span class="drugH1">Use: Off-Label: Adult</span><p>Elective induction of labor</p></div>
<div class="block mst drugH1Div" id="F205536"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (oxytocin IV) among its list of medications that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Oxytocin may be confused with OxyCONTIN</p>
<p style="text-indent:-2em;margin-left:4em;">Pitocin may be confused with PIT or Pitressin (names to describe vasopressin), pitolisant</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299808"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F205466"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Carbetocin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carboprost Tromethamine: May enhance the adverse/toxic effect of Oxytocic Agents. Specifically, oxytocic effects may be enhanced.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dinoprostone: May enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced. Management: Concomitant use of dinoprostone and oxytocin is not recommended. If used sequentially, monitor uterine activity closely. Administer oxytocin 30 minutes after removing dinoprostone vaginal insert and 6 to 12 hours after the application of dinoprostone gel.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Nasal): Oxytocin may enhance the hypertensive effect of EPHEDrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Oxytocin may enhance the hypertensive effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemeprost: May enhance the adverse/toxic effect of Oxytocin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Lofexidine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiSOPROStol: May enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced. Management: The manufacturer of misoprostol recommends avoiding concomitant use with oxytocin.  Misoprostol may augment effects of oxytocin, particularly when given within 4 hours of oxytocin initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Piperaquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Probucol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): Oxytocin may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of Oxytocin. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Oxytocin may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Toremifene.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F205479"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Small amounts of exogenous oxytocin are expected to reach the fetal circulation. When used as indicated, teratogenic effects would not be expected. Nonteratogenic adverse reactions are reported in the neonate as well as the mother.</p>
<p style="text-indent:0em;margin-top:2em;">Oxytocin is used for augmentation of labor in patients making slow progress through the first stage of spontaneous labor. The time to delivery is shortened by ~2 hours (Alhafez 2020).</p>
<p style="text-indent:0em;margin-top:2em;">When used for induction of labor, maternal and fetal conditions, cervical status, gestational age, and other factors should be considered. Indications for induction of labor are not absolute but may include abruptio placentae, chorioamnionitis, post-term pregnancy, preeclampsia/eclampsia, premature rupture of membranes, fetal compromise (eg, severe fetal growth restriction, isoimmunization, oligohydramnios), fetal demise, or maternal medical conditions (eg, diabetes mellitus, kidney disease, chronic pulmonary disease, chronic or gestational hypertension, antiphospholipid syndrome) (ACOG 2009). Oxytocin should not be used to induce labor when spontaneous labor or vaginal birth would otherwise be contraindicated (ACOG 2009; AWHONN [Simpson 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Although the prescribing information contains a boxed warning against use for non-medical induction of labor, oxytocin may be used off-label for the elective induction of labor at 39 weeks gestation. Details for this use come from the ARRIVE trial (A Randomized Trial of Induction Versus Expectant Management). The study included low risk nulliparous patients with singleton gestations. Eligible patients did not have conditions requiring delivery prior to 40 weeks gestation and had reliable information of gestational age based on ultrasound and date of last menstrual period. A specific dosing protocol for oxytocin was not used in the study. The study showed no statistical difference in the primary composite outcome of perinatal mortality and severe perinatal morbidity while noting that cesarean delivery rate was significantly lower in the induction of labor group. In addition, there was a lower rate of gestational hypertension and preeclampsia as well as a reduced need for neonatal respiratory support in the first 72 hours of life. The American College of Obstetricians and Gynecologists (ACOG) and the Society of Maternal-Fetal (SMFM) state that it is reasonable to offer elective induction of labor to pregnant patients who meet the trial criteria. The recommendations are conditional, based on the preferences of the patient as well as the resources available (ACOG 2018; Grobman 2018; SMFM 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Significant drug interactions exist (eg, dinoprostone, misoprostol), requiring dose/frequency adjustment or avoidance (ACOG 2009). Consult drug interactions database for more information.</p></div>
<div class="block brc drugH1Div" id="F205480"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Endogenous oxytocin mediates milk ejection. Administration of exogenous oxytocin may negatively impact breastfeeding. However, available studies have inconsistent results when evaluating the onset of lactogenesis, or the initiation and duration of breastfeeding. Outcomes may be influenced by study design, maternal dose, and indications for use (Buckley 2015; Erickson 2017; Fernández-Cañadas 2017; Fernández-Cañadas 2019; Gomes 2018).</p></div>
<div class="block mop drugH1Div" id="F205470"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Fluid intake and output during administration, uterine activity (tonus, amplitude, and frequency of contractions), maternal blood pressure; continuous electronic fetal heart rate monitoring in relation to uterine contractions.</p></div>
<div class="block pha drugH1Div" id="F205460"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Oxytocin stimulates uterine contractions by acting on receptors that trigger the release of intracellular calcium and local prostaglandin production. Oxytocin specific receptors are not present in the uterus until ~13 weeks' gestation and increase as pregnancy progresses and reach maximum concentration at term. Therefore, term pregnancies are more sensitive to lower oxytocin doses. The action of oxytocin is limited by the concentration of receptors in the smooth muscle of the uterus. Repeated doses may cause desensitization of the receptors and decreased response (Vallera 2017).</p></div>
<div class="block phk drugH1Div" id="F205476"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Uterine contractions: IM: 3 to 5 minutes; IV: ~1 minute </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: IM: 2 to 3 hours; IV: 1 hour </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 1 to 6 minutes; decreased in late pregnancy and during lactation</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (small amount unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F205481"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Pitocin | Syntocinon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Hipofisina | Veracuril</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Oxytocin apotex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ocin | Pitocin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Orastina | Syntocinon</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Syntocinon</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Oxitocina | Pitocin | Syntocinon</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ofost | Oxytocin avmc</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Oxitocina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Oxitocina | Pitocin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Sunnylabcin | Syntocinon</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Partolact medica</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Syntocinon</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Syntocinon</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Oxygrindeks</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ofost | Syntocinon</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Oxycod | Syntocinon</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Genox | Gynotocin | Itocin | Oxytin | Oxytomed | Oxyton | Pitocin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Syntocinon</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Atonin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Pepcinon | Tocinox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Jw oxytocin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ofost | Oxytocin panpharma</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Syntocinon</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Oxygrindeks | Syntocinon</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Oxytocin aurora medical | Oxytocin life | Pitocin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Oxytocin apotex</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ambitocyn | Cleartocin | Fetusin | Lavoxin | Ocitoxin | Oxitex | Oxitone | Oxynox | Solvoxine | Tocinox | Tranoxy</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Syntocinon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Syntocinon</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Oxitocina | Oxitocina hikma</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Veracuril</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Syntocinon</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Oxitocina panpharma | Oxitocina s</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Gynocin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Oxytocin Pilum</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ofost | Oxygrindeks</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Oxytocin synth</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Postuitrine | Synpitan | Syntocinon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Litocin | Pitocin | Piton S | Syntocinon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Oxitocina | Oxitocina sanderson | Veracuril</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Syntocinon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Spec oxytocin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF-38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30181338">
<a name="30181338"></a>Adnan N, Conlan-Trant R, McCormick C, Boland F, Murphy DJ. Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial. <i>BMJ</i>. 2018;362:k3546. doi: 10.1136/bmj.k3546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/30181338/pubmed" id="30181338" target="_blank">30181338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33345911">
<a name="33345911"></a>Alhafez L, Berghella V. Evidence-based labor management: first stage of labor (part 3). <i>Am J Obstet Gynecol MFM</i>. 2020;2(4):100185. doi:10.1016/j.ajogmf.2020.100185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/33345911/pubmed" id="33345911" target="_blank">33345911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.2018">
<a name="ACOG.2018"></a>American College of Obstetricians and Gynecologists (ACOG). Practice Advisory: clinical guidance for integration of the findings of the ARRIVE trial: labor induction versus expectant management in low-risk nulliparous women. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2018/08/clinical-guidance-for-integration-of-the-findings-of-the-arrive-trial. Published August 2018. Accessed September 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19623003">
<a name="19623003"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins - Obstetrics. ACOG practice bulletin No.107: induction of labor. <i>Obstet Gynecol.</i> 2009;114(2, pt 1):386-397. doi: 10.1097/AOG.0b013e3181b48ef5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/19623003/pubmed" id="19623003" target="_blank">19623003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28937571">
<a name="28937571"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. Practice bulletin No. 183: postpartum hemorrhage. <i>Obstet Gynecol</i>. 2017;130(4):e168-e186. doi: 10.1097/AOG.0000000000002351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/28937571/pubmed" id="28937571" target="_blank">28937571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34148721">
<a name="34148721"></a>Association of Women’s Health, Obstetric and Neonatal Nurses. Guidelines for active management of the third stage of labor using oxytocin: AWHONN practice brief number 12. <i>J Obstet Gynecol Neonatal Nurs</i>. 2021;50(4):499-502. doi:10.1016/j.jogn.2021.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/34148721/pubmed" id="34148721" target="_blank">34148721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33345875">
<a name="33345875"></a>Berghella V, Bellussi F, Schoen CN. Evidence-based labor management: induction of labor (part 2). <i>Am J Obstet Gynecol MFM</i>. 2020;2(3):100136. doi:10.1016/j.ajogmf.2020.100136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/33345875/pubmed" id="33345875" target="_blank">33345875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26834435">
<a name="26834435"></a>Buckley SJ. Executive summary of hormonal physiology of childbearing: evidence and implications for women, babies, and maternity care. <i>J Perinat Educ</i>. 2015;24(3):145-153. doi: 10.1891/1058-1243.24.3.145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/26834435/pubmed" id="26834435" target="_blank">26834435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20150347">
<a name="20150347"></a>Butwick AJ, Coleman L, Cohen SE, Riley ET, Carvalho B. Minimum effective bolus dose of oxytocin during elective Caesarean delivery. <i>Br J Anaesth</i>. 2010;104(3):338-343. doi: 10.1093/bja/aeq004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/20150347/pubmed" id="20150347" target="_blank">20150347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15516392">
<a name="15516392"></a>Carvalho JC, Balki M, Kingdom J, Windrim R. Oxytocin requirements at elective cesarean delivery: a dose-finding study. <i>Obstet Gynecol</i>. 2004;104(5, pt 1):1005-1010. doi: 10.1097/01.AOG.0000142709.04450.bd.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/15516392/pubmed" id="15516392" target="_blank">15516392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29240650">
<a name="29240650"></a>Drummond S. Oxytocin use in labor: legal implications. <i>J Perinat Neonatal Nurs.</i> 2018;32(1):34-42. doi:10.1097/JPN.0000000000000300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/29240650/pubmed" id="29240650" target="_blank">29240650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21415725">
<a name="21415725"></a>Dyer RA, Butwick AJ, Carvalho B. Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist. <i>Curr Opin Anaesthesiol</i>. 2011;24(3):255-261. doi: 10.1097/ACO.0b013e328345331c.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/21415725/pubmed" id="21415725" target="_blank">21415725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32600245">
<a name="32600245"></a>Ebada MA, Elmatboly AM, Baligh G. Intravenous oxytocin versus intramuscular oxytocin for the management of postpartum hemorrhage: a systematic review and meta-analysis. <i>Curr Drug Res Rev</i>. 2020;12(2):150-157. doi:10.2174/2589977512666200628013647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/32600245/pubmed" id="32600245" target="_blank">32600245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28759177">
<a name="28759177"></a>Erickson EN, Emeis CL. Breastfeeding outcomes after oxytocin use during childbirth: an integrative review. <i>J Midwifery Womens Health</i>. 2017;62(4):397-417. doi:10.1111/jmwh.12601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/28759177/pubmed" id="28759177" target="_blank">28759177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29754970">
<a name="29754970"></a>Fernández-Cañadas Morillo A, Durán Duque M, Hernández López AB, et al. Cessation of breastfeeding in association with oxytocin administration and type of birth. A prospective cohort study. <i>Women Birth</i>. 2019;32(1):e43-e48. doi:10.1016/j.wombi.2018.04.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/29754970/pubmed" id="29754970" target="_blank">29754970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28165755">
<a name="28165755"></a>Fernández-Cañadas Morillo A, Marín Gabriel MA, Olza Fernández I, et al. The relationship of the administration of intrapartum synthetic oxytocin and breastfeeding initiation and duration rates. <i>Breastfeed Med</i>. 2017;12:98-102. doi:10.1089/bfm.2016.0185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/28165755/pubmed" id="28165755" target="_blank">28165755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29523035">
<a name="29523035"></a>Gomes M, Trocado V, Carlos-Alves M, Arteiro D, Pinheiro P. Intrapartum synthetic oxytocin and breastfeeding: a retrospective cohort study. <i>J Obstet Gynaecol</i>. 2018;38(6):745-749. doi:10.1080/01443615.2017.1405924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/29523035/pubmed" id="29523035" target="_blank">29523035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30089070">
<a name="30089070"></a>Grobman WA, Rice MM, Reddy UM, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Labor induction versus expectant management in low-risk nulliparous women. <i>N Engl J Med</i>. 2018;379(6):513-523. doi:10.1056/NEJMoa1800566<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/30089070/pubmed" id="30089070" target="_blank">30089070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25421530">
<a name="25421530"></a>Guidelines for oxytocin administration after birth: AWHONN practice brief number 2. <i>J Obstet Gynecol Neonatal Nurs</i>. 2015;44(1):161-163. doi: 10.1111/1552-6909.12528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/25421530/pubmed" id="25421530" target="_blank">25421530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25909969">
<a name="25909969"></a>Kovacheva VP, Soens MA, Tsen LC. A randomized, double-blinded trial of a "rule of threes" algorithm versus continuous infusion of oxytocin during elective cesarean delivery. <i>Anesthesiology</i>. 2015;123(1):92-100. doi:10.1097/ALN.0000000000000682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/25909969/pubmed" id="25909969" target="_blank">25909969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10472877">
<a name="10472877"></a>Merrill DC, Zlatnik FJ. Randomized, double-masked comparison of oxytocin dosage in induction and augmentation of labor. <i>Obstet Gynecol.</i> 1999;94(3):455-463. doi:10.1016/s0029-7844(99)00338-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/10472877/pubmed" id="10472877" target="_blank">10472877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30865585">
<a name="30865585"></a>Muñoz M, Stensballe J, Ducloy-Bouthors AS, et al. Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. <i>Blood Transfus</i>. 2019;17(2):112-136. doi:10.2450/2019.0245-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/30865585/pubmed" id="30865585" target="_blank">30865585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WestWard.1">
<a name="WestWard.1"></a>Oxytocin injection [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; June 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Oxytocin injection [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pitocin.1">
<a name="Pitocin.1"></a>Pitocin (oxytocin) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20142654">
<a name="20142654"></a>Rajan PV, Wing DA. Postpartum hemorrhage: evidence-based medical interventions for prevention and treatment. <i>Clin Obstet Gynecol.</i> 2010;53(1):165-181. doi: 10.1097/GRF.0b013e3181ce0965.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/20142654/pubmed" id="20142654" target="_blank">20142654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36725134">
<a name="36725134"></a>Robinson D, Campbell K, Hobson SR, MacDonald WK, Sawchuck D, Wagner B. Guideline no. 432c: induction of labour. <i>J Obstet Gynaecol Can</i>. 2023;45(1):70-77.e3. doi:10.1016/j.jogc.2022.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/36725134/pubmed" id="36725134" target="_blank">36725134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26773243">
<a name="26773243"></a>Sentilhes L, Vayssière C, Deneux-Tharaux C, et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). <i>Eur J Obstet Gynecol Reprod Biol</i>. 2016;198:12-21. doi: 10.1016/j.ejogrb.2015.12.012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/26773243/pubmed" id="26773243" target="_blank">26773243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32778395">
<a name="32778395"></a>Simpson KR. Cervical ripening and labor induction and augmentation, 5th edition. <i>Nurs Womens Health</i>. 2020;24(4):S1-S41. doi:10.1016/j.nwh.2020.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/32778395/pubmed" id="32778395" target="_blank">32778395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smetzer.1">
<a name="Smetzer.1"></a>Smetzer J, Cohen M, eds. Best practice 17: safe oxytocin use. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2022;27(9):1-2.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30098985">
<a name="30098985"></a>Society of Maternal-Fetal (SMFM) Publications Committee. Electronic address: <a class="__cf_email__" data-cfemail="84f4f1e6f7c4f7e9e2e9aaebf6e3" href="/cdn-cgi/l/email-protection">[email protected]</a>. SMFM statement on elective induction of labor in low-risk nulliparous women at term: the ARRIVE trial. <i>Am J Obstet Gynecol</i>. 2019;221(1):B2-B4. doi:10.1016/j.ajog.2018.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/30098985/pubmed" id="30098985" target="_blank">30098985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36649339">
<a name="36649339"></a>Son M, Roy A, Grobman WA, et al. Maximum dose rate of intrapartum oxytocin infusion and associated obstetric and perinatal outcomes. <i>Obstet Gynecol</i>. 2023;141(2):379-386. doi:10.1097/AOG.0000000000005058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/36649339/pubmed" id="36649339" target="_blank">36649339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26974052">
<a name="26974052"></a>Sumikura H, Inada E. Uterotonics and tocolytics for anesthesiologists. <i>Curr Opin Anaesthesiol</i>. 2016;29(3):282-287. doi: 10.1097/ACO.0000000000000332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/26974052/pubmed" id="26974052" target="_blank">26974052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23974190">
<a name="23974190"></a>Trissel LA, Zhang Y, Douglas K, Kastango E. Extended stability of oxytocin in common infusion solutions. <i>Int J Pharm Compd</i>. 2006;10(2):156-158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/23974190/pubmed" id="23974190" target="_blank">23974190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20570503">
<a name="20570503"></a>Tsen LC, Balki M. Oxytocin protocols during cesarean delivery: time to acknowledge the risk/benefit ratio? <i>Int J Obstet Anesth</i>. 2010;19(3):243-245. doi:10.1016/j.ijoa.2010.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/20570503/pubmed" id="20570503" target="_blank">20570503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28526143">
<a name="28526143"></a>Vallera C, Choi LO, Cha CM, Hong RW. Uterotonic medications: oxytocin, methylergonovine, carboprost, misoprostol. <i>Anesthesiol Clin</i>. 2017;35(2):207-219. doi: 10.1016/j.anclin.2017.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/28526143/pubmed" id="28526143" target="_blank">28526143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20451894">
<a name="20451894"></a>Wei SQ, Luo ZC, Qi HP, Xu H, Fraser WD. High-dose vs low-dose oxytocin for labor augmentation: a systematic review. <i>Am J Obstet Gynecol.</i> 2010;203(4):296-304. doi: 10.1016/j.ajog.2010.03.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/20451894/pubmed" id="20451894" target="_blank">20451894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33252891">
<a name="33252891"></a>WHO recommendation on routes of oxytocin administration for the prevention of postpartum haemorrhage after vaginal birth [Internet]. Geneva: World Health Organization; 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/33252891/pubmed" id="33252891" target="_blank">33252891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32124015">
<a name="32124015"></a>Wu Y, Wang H, Wu QY, Liang XL, Wang J. A meta-analysis of the effects of intramuscular and intravenous injection of oxytocin on the third stage of labor. <i>Arch Gynecol Obstet</i>. 2020;301(3):643-653. doi:10.1007/s00404-020-05467-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/32124015/pubmed" id="32124015" target="_blank">32124015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32439242">
<a name="32439242"></a>Zhou YH, Xie Y, Luo YZ, Liu XW, Zhou J, Liu Q. Intramuscular versus intravenous oxytocin for the third stage of labor after vaginal delivery to prevent postpartum hemorrhage: a meta-analysis of randomized controlled trials. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2020;250:265-271. doi:10.1016/j.ejogrb.2020.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/32439242/pubmed" id="32439242" target="_blank">32439242</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9734 Version 279.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
